Trial results

Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus

NCT00299871 on ClinicalTrials.gov · last registry update 2014-01-28

An unusually large phase 2: 542 participants, more than double the 114 typical for the stage. The sponsor logged completion for August 2007. Primary outcome, as filed: HbA1c levels at baseline and endpoint (at 13 weeks). lixisenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.

Status

COMPLETED

Phase

P2

Drug

lixisenatide

Soliqua, Adlyxin

Sponsor

Sanofi

Sponsor type

Industry

Enrollment

542

Started

2006-02

Primary completion

2007-08 actual

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Primary outcome

HbA1c levels at baseline and endpoint (at 13 weeks).

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the lixisenatide page for this molecule’s full trial and approval history.